MannKind | MNKD - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
Adma Biologics USD 61.59M 14.07M 2025-12
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Insmed USD -162.1M 164.84M 2026-03
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
MacroGenics USD -14.93M 31.75M 2025-12
MannKind USD -16.37M 4.56M 2026-03
Merck USD 3.42B 3.32B 2025-12
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Novavax USD 17.9M 220.94M 2025-12
Novo Nordisk DKK 25.52B 8.29B 2025-09
Pfizer USD 5.18B 6.82B 2026-03
Sanofi EUR -1.16B 5.5B 2025-12
Xencor USD -128.64M 124.37M 2026-03